Structural Requirements for the Procoagulant Activity of Nucleic Acids

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Gansler, Julia ^a   Jaax, Miriam ^b   Leiting, Silke ^a   Appel, Bettina ^b   Greinacher, Andreas ^b   Fischer, Silvia ^a   Preissner, Klaus T ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DNA OLIGONUCLEOTIDE; KININOGEN; NUCLEIC ACID; OLIGOMER; PREKALLIKREIN; PROTEIN C; RNA OLIGONUCLEOTIDE; SMALL NUCLEOLAR RNA; THROMBIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DNA STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; MOLECULAR WEIGHT; PROTEIN DEGRADATION; PROTEIN DETERMINATION; RNA STRUCTURE; STRUCTURE ACTIVITY RELATION;

APTAMERS, NUCLEOTIDE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; COAGULANTS; HUMANS; INVERTED REPEAT SEQUENCES; KININOGEN, HIGH-MOLECULAR-WEIGHT; NUCLEIC ACID CONFORMATION; OLIGORIBONUCLEOTIDES; PHOSPHOPROTEINS; PREKALLIKREIN; PROTEIN BINDING; PROTEIN C; RNA, SMALL NUCLEAR; RNA-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870592500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050399     Document Type: Article

References (37)

1. Ratnoff OD, Saito H, (1979) Surface-mediated reactions. Curr Top Hematol 2: 1-57.
2. Colman RW, Schmaier AH, (1997) Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90: 3819-3843.
3. Cochrane CG, Griffin JH, (1982) The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 33: 241-306.
4. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL, (1984) In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood. 63: 1453-1459.
5. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, et al. (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104: 6388-6393.
6. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, et al. (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118: 3208-3218.
7. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, et al. (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139: 1143-1156.
8. Oehmcke S, Morgelin M, Herwald H, (2009) Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 1: 225-230.
9. Fischer S, Gerriets T, Wessels C, Walberer M, Kostin S, et al. (2007) Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. Blood 110: 2457-2465.
10. Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, et al. (2005) Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). Biochem J 385: 831-838.
11. Al-Homood IA, (2012) Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol 2012: 428269.
12. Lerner MR, Steitz JA, (1979) Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 76: 5495-5499.
13. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ, (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355: 564-566.
14. Muller J, Isermann B, Ducker C, Salehi M, Meyer M, et al. (2009) An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 16: 442-451.
15. Soundararajan S, Wang L, Sridharan V, Chen W, Courtenay-Luck N, et al. (2009) Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol 76: 984-991.
16. Hasegawa H, Sode K, Ikebukuro K, (2008) Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method. Biotechnol Lett 30: 829-834.
17. Chu BC, Orgel LE, (1992) The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 20: 5857-5858.
18. Fischer S, Nishio M, Dadkhahi S, Gansler J, Saffarzadeh M, et al. (2010) Expression and localisation of vascular ribonucleases in endothelial cells. Thromb Haemost 105: 345-355.
19. Reddi KK, Holland JF, (1976) Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci U S A 73: 2308-2310.
20. Scott CF, Colman RW, (1980) Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 65: 413-421.
21. Schapira M, Scott CF, Colman RW, (1981) Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 20: 2738-2743.
22. Scott CF, Schapira M, James HL, Cohen AB, Colman RW, (1982) Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 69: 844-852.
23. Thompson RE, Mandle R Jr, Kaplan AP, (1977) Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 60: 1376-1380.
24. Tait JF, Fujikawa K, (1987) Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 262: 11651-11656.
25. Mandle RJ, Colman RW, Kaplan AP, (1976) Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A 73: 4179-4183.
26. Kerbiriou DM, Bouma BN, Griffin JH, (1980) Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. J Biol Chem 255: 3952-3958.
27. Kattah NH, Kattah MG, Utz PJ, (2010) The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 233: 126-145.
28. Kaplan MJ, (2004) Apoptosis in systemic lupus erythematosus. Clin Immunol 112: 210-218.
29. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, et al. (2009) Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 5: e1000639.
30. Paul A, Avci-Adali M, Neumann B, Guo K, Straub A, et al. (2010) Aptamers influence the hemostatic system by activating the intrinsic coagulation pathway in an in vitro Chandler-Loop model. Clin Appl Thromb Hemost 16: 161-169.
31. Rosenberg JE, Drabkin HA, Lara Jr P, Harzstark AL, Figlin RA, et al. (2010) A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology 28, No 15_suppl (May 20 Supplement): 4590.
32. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, et al. (1999) Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732: 203-212.
33. Jilma-Stohlawetz P, Knobl P, Gilbert JC, Jilma B, (2012) The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 108: 284-290.
34. Russo Krauss I, Merlino A, Giancola C, Randazzo A, Mazzarella L, et al. (2011) Thrombin-aptamer recognition: a revealed ambiguity. Nucleic Acids Res 39: 7858-7867.
35. Wilson C, Keefe AD, (2006) Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol 10: 607-614.
36. Chelliserrykattil J, Ellington AD, (2004) Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22: 1155-1160.
37. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, et al. (1995) Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2: 683-695.